Effects of high-intensity focused ultrasound in the treatment of experimental neuroblastoma

Yang, Rong; Reilly, Clarence R.; Rescorla, Frederick J.; Sanghvi, Narendra T.; Fry, F. J.; Franklin, Thomas D.; Grosfeld, Jay L.

doi:10.1016/0022-3468(92)90321-w

Cited by 86 publications

(52 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the group 1, docetaxel slowed down tumoral growth without actually stopping it. Yang et al 7 cured 12 mice out of 15 with the C1300 neuroblastoma cells, thanks to the combination of HIFU and adriamycin administered concomitantly. This cure rate that is higher than ours is explained by the fact that the entire tumor was treated and not only 75% as was the case in our study.…”

Section: Discussionmentioning

confidence: 99%

“…The concept of combining HIFU and chemotherapy dates back to the beginning of the 1990s when studies proved that in vivo, this combination was synergic and superior to treatment with HIFU alone or chemotherapy alone. [6][7][8][9] This was notably demonstrated with adriamycin on C 1300 neuroblastoma, doxorubicin and cyclophosphamide on Morris hepatoma or more recently with mitomycin on urothelial carcinoma of the urinary bladder. 10 In 2005, we demonstrated for the first time that this HIFU/chemotherapy synergic effect also exists with the combination of paclitaxel and estramustin phosphate on Dunning tumors implanted subcutaneously in Copenhagen rats.…”

Section: Introductionmentioning

confidence: 93%

“…Two concepts might explain this phenomenon: the first is the belief that HIFU acts on tumor cells that are already weakened by chemotherapy administered 24 h before treatment; 5,8 the second belief is that it is the concomitant application of HIFU and chemotherapy that allows better intracellular diffusion of the chemotherapy and therefore an accrued cytotoxicity. [6][7][8]11 To distinguish the role of these two mechanisms we developed an experimental protocol that included an arm in which chemotherapy was administered 24 h before treatment by HIFU and an arm in which chemotherapy was administered concomitantly with HIFU treatment. The chemotherapy used in our experiment was docetaxel for which the half-life is slightly longer than 90 min when administered by i.p.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Influence of the docetaxel administration period (neoadjuvant or concomitant) in relation to HIFU treatment on the growth of Dunning tumors: results of a preliminary study

Paparel

Chapelon

Bissery

et al. 2007

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

The objective of this study was to evaluate mechanisms of the synergy between high intensityfocused ultrasound (HIFU) and docetaxel and to determine the best sequence of chemotherapy administration in relation to HIFU treatment for obtaining optimum control of tumoral growth. A total of 15 days after s.c. implantation of the tumor, 52 Copenhagen rats studied were randomized in 4 groups of 13: controls, docetaxel alone (group 1), HIFU and docetaxel concomitant (group 2) and HIFU and docetaxel administered 24 h before treatment (group 3). The number of HIFU shots was calculated in order to cover 75% of the tumor volume. The effects of docetaxel, HIFU and their interaction on tumor volumes were analyzed using a linear regression. The distributions of the tumor volumes were significantly greater in the control group than in the group 1 (P ¼ 0.002) and than in both groups 2 and 3 (Po0.0001 and P ¼ 0.0001). These volumes were also significantly greater in group 1 than in both groups 2 and 3 and there was no difference between the groups 2 and 3. The tumor doubling times were 7.8 days for the group 1, 43.8 days for the group 2, 16.1 days for the group 3 and 5.9 days for the controls. The mechanism of the synergy between HIFU and docetaxel on the growth of Dunning tumors is apparently multifaceted. The results are encouraging because in the two groups of rats treated with the combination of HIFU and docetaxel, the percentage of complete remission was approximately 30%.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 93%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Influence of the docetaxel administration period (neoadjuvant or concomitant) in relation to HIFU treatment on the growth of Dunning tumors: results of a preliminary study

Paparel

Chapelon

Bissery

et al. 2007

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…Another concern is that HIFU may promote the spread of metastases. Small animal studies have shown that HIFU does not increase the risk of metastatic spread (Oosterhof et al, 1997), and there is evidence that ablative therapies may upregulate the response of host immune system to subsequent tumour challenge (Yang et al, 1992;den Brok et al, 2004).…”

Section: Kidneymentioning

confidence: 99%

The safety and feasibility of extracorporeal high-intensity focused ultrasound (HIFU) for the treatment of liver and kidney tumours in a Western population

et al. 2005

View full text Add to dashboard Cite

High-intensity focused ultrasound (HIFU) provides a potential noninvasive alternative to conventional therapies. We report our preliminary experience from clinical trials designed to evaluate the safety and feasibility of a novel, extracorporeal HIFU device for the treatment of liver and kidney tumours in a Western population. The extracorporeal, ultrasound-guided Model-JC Tumor Therapy System (HAIFUt Technology Company, China) has been used to treat 30 patients according to four trial protocols. Patients with hepatic or renal tumours underwent a single therapeutic HIFU session under general anaesthesia. Magnetic resonance imaging 12 days after treatment provided assessment of response. The patients were subdivided into those followed up with further imaging alone or those undergoing surgical resection of their tumours, which enabled both radiological and histological assessment. HIFU exposure resulted in discrete zones of ablation in 25 of 27 evaluable patients (93%). Ablation of liver tumours was achieved more consistently than for kidney tumours (100 vs 67%, assessed radiologically). The adverse event profile was favourable when compared to more invasive techniques. HIFU treatment of liver and kidney tumours in a Western population is both safe and feasible. These findings have significant implications for future noninvasive image-guided tumour ablation.

show abstract

“…4,16,17 HIFU treatment also has been shown to stimulate patient immunity against tumors and inhibit the growth of remaining tumors, [18][19][20] which reduce the metastatic ability of tumors. In this study, all patients had late stage malignant tumors, and the original tumors were removed by conventional surgery, chemotherapy or radiotherapy.…”

Section: Discussionmentioning

confidence: 99%

Superficial malignant tumors: Non-invasive treatment with ultrasonographically guided high-intensity focused ultrasound

Li¹,

Zhang²,

Rong³

et al. 2009

Cancer Biology & Therapy

View full text Add to dashboard Cite

Effects of high-intensity focused ultrasound in the treatment of experimental neuroblastoma

Cited by 86 publications

References 7 publications

Influence of the docetaxel administration period (neoadjuvant or concomitant) in relation to HIFU treatment on the growth of Dunning tumors: results of a preliminary study

Influence of the docetaxel administration period (neoadjuvant or concomitant) in relation to HIFU treatment on the growth of Dunning tumors: results of a preliminary study

The safety and feasibility of extracorporeal high-intensity focused ultrasound (HIFU) for the treatment of liver and kidney tumours in a Western population

Superficial malignant tumors: Non-invasive treatment with ultrasonographically guided high-intensity focused ultrasound

Contact Info

Product

Resources

About